Cargando…

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease

PURPOSE: We aimed to investigate associations between tau pathology and relative cerebral blood flow (rCBF), and their relationship with cognition in Alzheimer’s disease (AD), by using a single dynamic [(18)F]flortaucipir positron emission tomography (PET) scan. METHODS: Seventy-one subjects with AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Denise, Wolters, Emma E., Verfaillie, Sander C. J., Coomans, Emma M., Timmers, Tessa, Tuncel, Hayel, Reimand, Juhan, Boellaard, Ronald, Windhorst, Albert D., Scheltens, Philip, van der Flier, Wiesje M., Ossenkoppele, Rik, van Berckel, Bart N. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680306/ https://www.ncbi.nlm.nih.gov/pubmed/32462397 http://dx.doi.org/10.1007/s00259-020-04831-w

Ejemplares similares

Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2022)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
por: Visser, Denise, et al.
Publicado: (2023)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET study
por: Schoonhoven, Deborah N, et al.
Publicado: (2023)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
por: Coomans, Emma M., et al.
Publicado: (2021)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Genetically identical twins show comparable tau PET load and spatial distribution
por: Coomans, Emma M, et al.
Publicado: (2022)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease
por: Singleton, Ellen, et al.
Publicado: (2021)

Kinetics and 28-day test–retest repeatability and reproducibility of [(11)C]UCB-J PET brain imaging
por: Tuncel, Hayel, et al.
Publicado: (2020)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Validation and test–retest repeatability performance of parametric methods for [(11)C]UCB-J PET
por: Tuncel, Hayel, et al.
Publicado: (2022)

Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
por: Verfaillie, Sander C. J., et al.
Publicado: (2015)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nr9cgfv4khe5i0689br6049bco